Shanghai Biotech Pipeline Targets (Zhangjiang Core)
Real-time target alignment
Targeting Claudin18.2 high-affinity gastric phenotypes with CAR-T vectors pioneered in Shanghai centers, outperforming Western trials in clinical bed availability.
Shanghai Fast-Track
Investigator-Initiated Trial (IIT)
Median Lead Time
52 Days
Regulatory Gate: Hospital IRB / Institutional Ethics Committee
Cell Manufacturing Turnaround: 14 to 18 Days (Zhangjiang Facility)
Inpatient Stay Requirement: 21 Days (ICU Backed CRS Monitoring)
Compassionate Access Feasibility: Rapid enrolment under Article 19 / IIT provision
US Standard Route
FDA Expanded Access / IND Phase I
Median Lead Time
210 Days
Regulatory Gate: FDA IND & Multi-Center IRB Authorization
Cell Manufacturing Turnaround: 28 to 42 Days (Centralized Commercial Lab)
Inpatient Stay Requirement: 14 to 28 Days (Standard REMS Protocol)
Access Hurdle: Strict slots, protracted single-patient compassionate IND
Milestone Trajectory & Biological Clearances
Protocol Days from Acceptance
D0: Path Review
D15: IRB/HGRAC
D30: Apheresis
D48: Infusion
D70: Primary Efficacy
Specimen Shipping
Fast-track Clearance
Bioreactor Run
CRS Inpatient Ward
PET-CT & ctDNA Scan
Clinical Safety Precaution: Experimental cell therapy protocols under IIT pathways require mandatory on-site hospitalization for cytokine release syndrome (CRS) surveillance with Tocilizumab and corticosteroid standby at top Shanghai tertiary academic centers.
Cross-Border Clinical Evaluation Dossier Preview
Generating dossier...